Dual Listing: Oasmia trusts in HAARMANN with regard to its dual listing

Oasmia Pharmaceutical AB, a company active in the pharmaceutical sector, has been admitted to the regulated market of Frankfurt Stock Exchange; first day of trading is 24 January 2011

Oasmia Pharmaceutical AB with its registered business seat in Uppsala, Sweden, has been approved to the regulated market NASDAQ OMX of the stock exchange in Stockholm since June 2010. For the purpose of broadening its investors' basis, Oasmia Pharmaceutical AB has conducted a dual listing to the regulated market of the Frankfurt Stock Exchange. Oasmia Pharmaceutical AB develops innovative active pharmaceutical ingredients in the sectors human and veterinary oncology on nanotechnologic basis. The company expects final approvals of several active pharmaceutical ingredients in 2011 and 2012.

Oasmia Pharmaceutical AB will be the first Swedish company listed in the regulated market of the Frankfurt Stock Exchange. The company has deliberately decided in favour of the regulated market and against the open market in order to guarantee the highest possible degree of transparency vis-à-vis its investors.

During the process of dual listing which was without precedent regarding a Swedish company Oasmia Pharmaceutical AB had been advised legally by HAARMANN and capital market related by Silvia Quandt & Cie. AG together with biw Bank für Investments und Wertpapiere AG and Autenrieth Capital GmbH & Co. KG.